Targeted knockdown of XDH reduces hyperuricaemia and renal damage in UOX-/- mice, suggesting therapeutic potential.
) hyperuricaemia mouse model. Our results demonstrated that GalNAc-siXDH can reduce serum urate levels, and alleviate renal damage including inflammation and fibrosis, indicating that GalNAc-siXDH is a potential therapeutic candidate for the treatment of hyperuricaemia.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: